{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T22:30:29Z","timestamp":1792621829681,"version":"4.5.0"},"reference-count":28,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,11,15]],"date-time":"2024-11-15T00:00:00Z","timestamp":1731628800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100015258","name":"Zhejiang\u00a0Provincial\u00a0People's\u00a0Hospital","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100015258","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Inflammatory myofibroblastic tumors (IMTs) are rare soft-tissue neoplasms. Accordingly, there is no standardized therapy for unresectable or advanced IMT. Chemotherapy, radiotherapy, and targeted molecular therapy play an important role in unresectable or advanced IMT.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case presentation<\/jats:title>\n                    <jats:p>We present a 54-year-old man with a cough and chest distress case report. The thoracic surgeon performed the right upper pulmonary occupying lesion wedge resection and enlarged lymph node excision biopsy. Pathologic diagnosis revealed that the morphology of \u201cright upper lung mass\u201d was considered as Inflammatory Myofibroblastic Tumor (IMT). Radiotherapy was indicated at a high dose: 5400cGy in 27 fractions of 2Gy over 5 weeks were delivered combined with cisplatin. The patient was given a CT\/MRI and hematological index every 3 months and experienced no more adverse events. The patient survives with no tumor recurrence as of the last follow-up. Progression-free survival (PFS) exceeded 5 years.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>We have reviewed the literature and summarized and discussed the radiotherapy treatment options and challenges for IMT. We first reported high-dose radiotherapy combined with chemotherapy treatment for unresectable IMT. Concurrent radiochemotherapy may be considered an intensive treatment for local progress, local recurrence, and nonresectable IMT patients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2024.1395787","type":"journal-article","created":{"date-parts":[[2024,11,15]],"date-time":"2024-11-15T01:15:20Z","timestamp":1731633320000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":5,"title":["Case report: The role and value of radiotherapy in treatment of inflammatory myofibroblastic tumor"],"prefix":"10.3389","volume":"14","author":[{"given":"Haiwei","family":"Guo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingyun","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juanjuan","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruiqi","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiping","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaodong","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haibo","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,11,15]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1097\/PAT.0000000000000050","article-title":"WHO classification of soft tissue tumours: an update based on the 2013 (4th) edition","volume":"46","author":"Jo","year":"2014","journal-title":"Pathology"},{"key":"B2","doi-asserted-by":"publisher","first-page":"100768","DOI":"10.1016\/j.currproblcancer.2021.100768","article-title":"Inflammatory myofibroblastic tumor: molecular landscape, targeted therapeutics, and remaining challenges","volume":"45","author":"Mahajan","year":"2021","journal-title":"Curr Probl Cancer"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1097\/01.pas.0000213393.57322.c7","article-title":"Inflammatory myofibroblastic tumor: comparison of clinicopathologic, histologic, and immunohistochemical features including ALK expression in atypical and aggressive cases","volume":"31","author":"Coffin","year":"2007","journal-title":"Am J Surg Pathol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.sjopt.2018.04.001","article-title":"Inflammatory myofibroblastic tumor of the orbit: A clinico-pathological study of 25 cases","volume":"32","author":"Strianese","year":"2018","journal-title":"Saudi J Ophthalmol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"e1068","DOI":"10.7759\/cureus.1068","article-title":"Efficiency of crizotinib on an ALK-positive inflammatory myofibroblastic tumor of the central nervous system: A case report","volume":"9","author":"Chennouf","year":"2017","journal-title":"Cureus"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2019.12.021","article-title":"Inflammatory myofibroblastic tumor: The experience of the European pediatric Soft Tissue Sarcoma Study Group (EpSSG)","volume":"127","author":"Casanova","year":"2020","journal-title":"Eur J Cancer"},{"key":"B7","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/s43046-020-00038-0","article-title":"Inflammatory myofibroblastic tumor of maxillary sinus successfully treated with radiotherapy and corticosteroid: report of a rare case","volume":"32","author":"Biswas","year":"2020","journal-title":"J Egypt Natl Canc Inst"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3892\/ol.2015.3708","article-title":"Successful combination chemotherapy for metastatic inflammatory myofibroblastic tumor: A case report","volume":"10","author":"Inadomi","year":"2015","journal-title":"Oncol Lett"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1038\/modpathol.3880352","article-title":"ALK1 and p80 expression and chromosomal rearrangements involving 2p23 in inflammatory myofibroblastic tumor","volume":"14","author":"Coffin","year":"2001","journal-title":"Mod Pathol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3109\/08880018.2013.816810","article-title":"Inflammatory myofibroblastic tumors in childhood","volume":"30","author":"Mehta","year":"2013","journal-title":"Pediatr Hematol Oncol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.v116:1","article-title":"Inflammatory myofibroblastic tumors in childhood: a report from the Italian Cooperative Group studies","volume":"116","author":"Alaggio","year":"2010","journal-title":"Cancer"},{"key":"B12","article-title":"Comparison of DNA ploidy, histologic, and immunohistochemical findings with clinical outcome in inflammatory myofibroblastic tumors","volume":"12","author":"Hussong","year":"1999","journal-title":"Mod Pathol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3892\/ol.2015.3297","article-title":"Recurrent inflammatory myofibroblastic tumor of the inguinal region: A case report and review of the literature","volume":"10","author":"Zhang","year":"2015","journal-title":"Oncol Lett"},{"key":"B14","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1186\/1746-1596-8-147","article-title":"Inflammatory myofibroblastic tumor with RANBP2 and ALK gene rearrangement: a report of two cases and literature review","volume":"8","author":"Li","year":"2013","journal-title":"Diagn Pathol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.4067\/S0034-98872015000700017","article-title":"Peritoneal myofibroblastic tumor successfully treated with infliximab: Report of one case","volume":"143","author":"Gr\u00fcnholz","year":"2015","journal-title":"Rev Med Chil"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1053\/jpsu.2000.18340","article-title":"Treatment of pseudotumors with nonsteroidal antiinflammatory drugs","volume":"35","author":"Su","year":"2000","journal-title":"J Pediatr Surg"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1038\/s41379-019-0406-6","article-title":"Infantile inflammatory myofibroblas tic tumors: clinicopathological and molecular characterization of 12 cases","volume":"33","author":"Lopez-Nunez","year":"2020","journal-title":"Mod Pathol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-14-0377","article-title":"Inflammatory myofibroblastic tumors harbor multiple potentially actionable kinase fusions","volume":"4","author":"Lovly","year":"2014","journal-title":"Cancer Discovery"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2018.12.016","article-title":"Case report: crizotinib is effective in a patient with ROS1-rearranged pulmonary inflammatory myofibroblastic tumor","volume":"128","author":"Mai","year":"2019","journal-title":"Lung Cancer"},{"key":"B20","doi-asserted-by":"publisher","first-page":"3191","DOI":"10.1158\/1538-7445.AM2020-3191","article-title":"Abstract 3191: Detection of molecular drivers in inflammatory myofibroblastic tumor: Study on archival tissue from EORTC 90101 CREATE phase II clinical trial","volume":"80","author":"Sch\u00f6ffski","year":"2020","journal-title":"Cancer Res"},{"key":"B21","doi-asserted-by":"publisher","first-page":"101202","DOI":"10.1016\/j.esmoop.2023.101202","article-title":"Natural history and treatment efficacy in an ambispective case series of NTRK-rearranged mesenchymal tumors","volume":"8","author":"Dufresne","year":"2023","journal-title":"ESMO Open"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.08.2232","article-title":"Diagnosis and management of tropomyosin receptor kinase (TRK) fusion sarcomas: Expert recommendations from the World Sarcoma Network","volume":"31","author":"Demetri","year":"2020","journal-title":"Ann Oncol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"NP1","DOI":"10.1177\/0300891619838333","article-title":"Successful role of adjuvant radiotherapy in a rare case of tracheal inflammatory myofibroblastic tumor: a case report","volume":"105","author":"Lisi","year":"2019","journal-title":"Tumori"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.328","article-title":"Inflammatory myofibroblastic tumor of the left sphenoid and cavernous sinus successfully treated with partial resection and high dose radiotherapy: case report and review of the literature","volume":"7","author":"Gabel","year":"2015","journal-title":"Cureus"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinimag.2016.09.012","article-title":"Inflammatory myofibroblastic tumor of mediastinum with esophageal and bronchial invasion: a case report and literature review","volume":"43","author":"Gorolay","year":"2017","journal-title":"Clin Imaging"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.otohns.2006.01.016","article-title":"Inflammatory pseudotumor involving the skull base: response to steroid and radiation therapy","volume":"135","author":"Lee","year":"2006","journal-title":"Otolaryngol Head Neck Surg"},{"key":"B27","doi-asserted-by":"publisher","first-page":"103646","DOI":"10.1155\/2013\/103646","article-title":"Inflammatory myofibroblastic tumour of the skull base","volume":"2013","author":"Maire","year":"2013","journal-title":"Case Rep Otolaryngol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/j.canrad.2019.07.157","article-title":"Combination of chemotherapy and radiotherapy: A thirty years evolution","volume":"23","author":"Hennequin","year":"2019","journal-title":"Cancer Radiother"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2024.1395787\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,15]],"date-time":"2024-11-15T01:15:23Z","timestamp":1731633323000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2024.1395787\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,15]]},"references-count":28,"alternative-id":["10.3389\/fonc.2024.1395787"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2024.1395787","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,15]]},"article-number":"1395787"}}